



INFLAMMATORY SKIN DISEASES (OTHER THAN ATOPIC DERMATITIS & PSORIASIS)

## APPLICATION OF MIXTURE OF BETAMETHASONE PROPIONATE AND CALCIPOTRIOL REPLACING THE INDICATION FOR SURGICAL TREATMENT

Joonsoo Park<sup>(1)</sup> - Nuri Na<sup>(1)</sup> - Yong Woo Choi<sup>(1)</sup> - Osung Kwon<sup>(1)</sup>

*School Of Medicine, Catholic University Of Daegu, Department Of Dermatology, Daegu,  
Republic Of Korea<sup>(1)</sup>*

**Background :** Divobet® is a mixed preparation of betamethasone propionate and calcipotriol, and is used as a topical application of plaque psoriasis. The principle of Divobet® is to reduce inflammation and to normalize the cell growth. But, the use of Divobet® is limited to plaque psoriasis so far and the frequency of use for other diseases is low. In our case, the patient diagnosed Clear cell acanthoma (CCA), and in consideration of patient general condition, used Divobet® for 1 month. Until now, the etiology of CCA has not been elucidated, recently it is considered to be one of the most likely hypothesis of the result of inflammatory reaction.

**Observation :** A 65-year-old women complained for erythematous scaly patch around operation scar for 10 days. She was HBV related liver cirrhosis patients and got liver transplantation operation for 2 years ago. There was no specific familial, past history and laboratory test. We diagnosed CCA with histopathologic results, and treated with Divobet® daily appliance for 1 month. 1 month later, lesion were improved. This case is a rare case of psoriasiform dermatitis occurred at the wound site and could be diagnosed as clear cell neoplasm, which can be considered as further evidence for inflammatory reaction in etiology. Also, there is no reported a case of CCA treated with Divobet® until now.

**Key message :** Divobet® was originally used for psoriasis. But when was used for CCA, which is an operative indication, its effect was confirmed and this case give new proposal for etiology and treatment of CCA.

